Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$4.75 USD
+0.04 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.76 +0.01 (0.21%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DSGN 4.75 +0.04(0.85%)
Will DSGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DSGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DSGN
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
DSGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DSGN
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC? Portfolio
Design Therapeutics expects cash to fund expenses into 2029
Design Therapeutics reports Q2 EPS (21c), consensus (23c)